DOMA Perpetual nominates three directors to Pacira board

DOMA Perpetual Capital, which owns about 7.5% of Pacira BioSciences, is pressing for three board seats and urging the company to consider a sale amid concerns over litigation strategy and weak long-term share performance. Pacira reported Q1 2026 EPS of $0.60 versus $0.56 expected and revenue of $177 million versus $172.46 million expected, but the stock still sold off after hours. The company also faces ongoing patent disputes, including a 2025 settlement allowing generic competition for EXPAREL starting in 2030.

Analysis

The equity is increasingly trading like an asset on borrowed time: when a single product drives the vast majority of value and the patent runway is visibly shortening, the market stops underwriting steady execution and starts pricing in terminal optionality. That makes the current debate less about one quarter’s beat and more about whether management can convert near-term cash flow into a credible exit before the litigation overhang and generic clock compress the multiple further.

The most important second-order effect is that activism here can catalyze a faster strategic process even without a proxy win. If the board senses a real contest, it may become more willing to engage buyers, settle disputes on less favorable terms, or accelerate capital allocation changes; in other words, the pressure can improve the odds of a transaction before 2030, but it can also force concessions that reduce standalone earnings power first. That creates a sharp skew: limited upside if the status quo persists, but meaningful re-rating potential if a process begins and credible acquirers view the asset as a cash-rich, patent-risk-distressed bolt-on.

From a trading standpoint, the near-term risk is not the operating print—it is headline and event risk around board control, legal rulings, and strategic review announcements over the next 1-3 months. The more structural risk is that any apparent fundamental strength gets overwhelmed by the market’s willingness to look through current earnings once generic entry timing is locked in. Conversely, the stock can rally hard if a buyer emerges or if management credibly abandons litigation spend and signals capital return, because the current valuation is still low enough to attract value and event-driven capital.

The consensus may be underestimating how much litigation exhaustion matters for a mid-cap healthcare name with high gross margins but an increasingly finite moat. The market often treats patent disputes as binary, but here the real issue is path dependency: each quarter spent fighting is a quarter lost on process, and every delay increases the chance the eventual exit price gets anchored to declining durability rather than current earnings.

Key Decisions for Investors

• Long PCRX only as an event-driven position into the June 9, 2026 vote; use a 4-8 week horizon and size for a 2-3x upside if a sale process is announced, with a hard stop if proxy support collapses.
• For hedged exposure, pair long PCRX / short IHI or a basket of large-cap healthcare names over the next 1-2 months; thesis is idiosyncratic event alpha versus lower-vol sector beta.
• Buy short-dated PCRX calls or call spreads ahead of the annual meeting if borrow is tight and activism momentum builds; risk/reward is favorable for a catalyst but avoid naked stock if litigation headlines can gap it down.
• If holding PCRX, trim on any rally tied to earnings beats rather than strategic action; the cleaner monetization point is an explicit board/strategic review announcement, not operating outperformance.
• For more conservative books, avoid outright shorts until after the proxy outcome; the stock can squeeze sharply on board-change speculation even if the long-term patent story remains deteriorating.